Details for Patent: 9,181,223

« Back to Dashboard

Which drugs does patent 9,181,223 protect, and when does it expire?

Patent 9,181,223 protects ROMVIMZA and is included in one NDA.

This patent has forty-five patent family members in nineteen countries.

Summary for Patent: 9,181,223

Title:	2-aminopyrimidin-6-ones and analogs exhibiting anti-cancer and anti-proliferative activities
Abstract:	Described are compounds of Formula I which find utility in the treatment of cancer, autoimmune diseases and metabolic bone disorders through inhibition of c-FMS (CSF-1R), c-KIT, and/or PDGFR kinases. These compounds also find utility in the treatment of other mammalian diseases mediated by c-FMS, c-KIT, or PDGFR kinases.
Inventor(s):	Michael D. Kaufman, Daniel L. Flynn, Yumi AHN, Lakshminarayana Vogeti, Timothy Malcolm Caldwell
Assignee:	Deciphera Pharmaceuticals LLC
Application Number:	US14/214,171
Patent Claim Types: see list of patent claims	Use; Composition; Delivery;

Drugs Protected by US Patent 9,181,223

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Deciphera Pharms	ROMVIMZA	vimseltinib	CAPSULE;ORAL	219304-001	Feb 14, 2025		RX	Yes	No			Y	Y
Deciphera Pharms	ROMVIMZA	vimseltinib	CAPSULE;ORAL	219304-002	Feb 14, 2025		RX	Yes	No			Y	Y
Deciphera Pharms	ROMVIMZA	vimseltinib	CAPSULE;ORAL	219304-003	Feb 14, 2025		RX	Yes	Yes			Y	Y

International Family Members for US Patent 9,181,223

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2968286		301373	Netherlands
European Patent Office	2968286		CR 2026 00012	Denmark
European Patent Office	2968286		2026C/708	Belgium
European Patent Office	2968286		LUC50045	Luxembourg
European Patent Office	2968286		122026000023	Germany